Roots Analysis
MAY 21, 2024
In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the main causes of drug failure in obtaining approval authorization.
Delveinsight
SEPTEMBER 8, 2021
As per DelveInsight’s report on Benlysta (Belimumab) market forecast , the sale of Belimumab has kept on increasing year after year. Currently, the SLE therapeutics market is revolving around only one drug i.e It is the top-selling medication in the market. Anifrolumab (MEDI-546). Baricitinib (INCB-028050).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Delveinsight
FEBRUARY 16, 2021
Numerous immunotherapy-based combinations are already trying in the old game of gleek to stake up some share in previously untreated, metastatic kidney cancer; however, the market seems to expand as the new entrants continue to make their entry. Padcev is a first-in-class antibody-drug conjugate (ADC) directed against Nectin-4, a protein.
Roots Analysis
MARCH 13, 2022
In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. Future Evolution of Biopharmaceutical Excipient Manufacturing Market.
pharmaphorum
FEBRUARY 25, 2021
All told, 80% of the patients have now been treated with this less frequent treatment regimen for more than two years with the efficacy maintained, according to the partners, and no new patients have developed antibodies against the drug – a perennial concern with ERT and something that can reduce its effectiveness.
XTalks
AUGUST 30, 2022
CNS drugs take more than a year longer to develop and are less than half as likely to receive marketing approval compared to other drugs, according to a 2014 study by the Tufts Center for the Study of Drug Development. What About Small Proteins and Antibodies Reaching Extracellular CNS Targets? The patients are waiting!
The Pharma Data
MARCH 11, 2021
Presentation Title: Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD). Session Date and Time: Monday, April 12, 2021 1:30 PM – 3:15 PM ET. Abstract Number: 1236. Session Category: Experimental and Molecular Therapeutics. Session Title: Novel Antitumor Agents.
Expert insights. Personalized for you.
40 
Let's personalize your content